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Burkholderia cepacia has emerged as an important pulmonary pathogen in immunocompromised patients
and in patients with cystic fibrosis (CF). Little is known about the virulence factors and pathogenesis of B.
cepacia, although the persistent and sometimes invasive infections caused by B. cepacia suggest that the
organism possesses mechanisms for both cellular invasion and evasion of the host immune response. In this
study, cultured human cells were used to analyze the invasion and intracellular survival of B. cepacia J2315,
a highly transmissible clinical isolate responsible for morbidity and mortality in CF patients. Quantitative
invasion and intracellular growth assays demonstrated that B. cepacia J2315 was able to enter, survive, and
replicate intracellularly in U937-derived macrophages and A549 pulmonary epithelial cells. Transmission
electron microscopy of infected macrophages confirmed the presence of intracellular B. cepacia and showed
that intracellular bacteria were contained within membrane-bound vacuoles. An environmental isolate of B.
cepacia, strain J2540, was also examined for its ability to invade and survive intracellularly in cultured human
cells. J2540 entered cultured macrophages with an invasion frequency similar to that of the clinical strain, but
it was less invasive than the clinical strain in epithelial cells. In marked contrast to the clinical strain, the
environmental isolate was unable to survive or replicate intracellularly in either cultured macrophages or
epithelial cells. Invasion and intracellular survival may play important roles in the ability of virulent strains
of B. cepacia to evade the host immune response and cause persistent infections in CF patients.
The gram-negative bacterium Burkholderia cepacia causes
serious opportunistic infections in humans and has recently
emerged as an important pulmonary pathogen in patients with
cystic fibrosis (CF) (7, 8, 11, 24). In CF patients the clinical
outcome of B. cepacia colonization can vary from maintenance
of a normal respiratory function to a rapid and ultimately fatal
clinical decline (11, 22). This latter condition, referred to as “B.
cepacia syndrome,” occurs in approximately 25% of CF pa-
tients and is characterized by fever, acute necrotizing pneumo-
nia and, in some cases, bacteremia (7). The specific mecha-
nisms by which B. cepacia is able to subvert host defense
mechanisms, invade deeper tissues of the lung, and ultimately
become blood-borne are poorly understood. Compounding
this lack of knowledge is the inherent resistance of B. cepacia
to multiple antibiotics, which has made treatment of B. cepacia
infections especially difficult (14, 21). Once a CF patient is
colonized with B. cepacia, the organism is rarely eradicated.
There is growing evidence that the persistent infections
caused by B. cepacia may be due, in part, to the ability of the
organism to invade and survive intracellularly in human cells.
Two of the main cell types encountered by B. cepacia infecting
the CF lung are respiratory epithelial cells and pulmonary
macrophages. B. cepacia organisms have been observed in tra-
cheal epithelial cells harvested at the time of autopsy from a
CF patient (J. L. Burns, D. K. Clark, and C. D. Wadsworth,
Proc. 6th Annu. N. Am. Cystic Fibrosis Conf., abstr. 201, 1992).
B. cepacia has also been shown to invade and survive in cul-
tured respiratory epithelial cells (2). In contrast to epithelial
cells, the interaction between B. cepacia and macrophages has
received little attention (7). Since pulmonary macrophages
represent a first line of defense within the CF lung, the ability
of B. cepacia to enter and survive within macrophages could
provide a mechanism for evasion of the host immune response
and may help to explain the reported ability of B. cepacia to
achieve prolonged pulmonary colonization despite a pro-
nounced antibody response (17). Moreover, an intracellular
niche may also explain the persistence of B. cepacia in the CF
lung despite the use of antibiotics with demonstrated activity
against the organism in vitro (5).
B. cepacia can be cultured from a range of natural environ-
ments, including soil, water, and plants (3). The pathogenic
potential of environmental isolates and their genetic relation-
ship to clinical strains responsible for severe and sometimes
fatal pulmonary infections is an important, yet unresolved is-
sue. One clinical strain in particular, J2315, has been respon-
sible for epidemic outbreaks and increased mortality in CF
patients (12, 20, 25). Strain J2315 expresses an unusual cable-
like pilus that has been shown to play a role in adherence to CF
mucin and airway respiratory epithelial cells (25). Other stud-
ies have demonstrated that J2315 exoproducts stimulate inter-
leukin-8 (IL-8) release from cultured lung epithelial cells and
peripheral blood monocytes (18). More recently, it has been
shown that strain J2315 produces a hemolytic toxin that in-
duces apoptosis (programmed cell death) in cultured macro-
phages (9). Taken together, these findings suggest that strain
J2315 possesses mechanisms for both host cell invasion and
evasion of the host immune response. A cell culture model for
both invasion and intracellular survival would be a valuable
tool to further define these processes and determine their role
in the pathogenesis of B. cepacia.
In this study, we established a macrophage model of invasion
and intracellular survival for B. cepacia. We examined the
ability of B. cepacia strain J2315, as well as an environmental
isolate of B. cepacia, to enter and survive intracellularly in
cultured human macrophages, as well as in respiratory epithe-
lial cells. Our findings suggest that invasion and intracellular
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survival may play important roles in the ability of virulent
strains of B. cepacia to evade the host immune response and
cause persistent and sometimes fatal infections in CF patients.
MATERIALS AND METHODS
Bacterial strains and growth conditions. Two strains of B. cepacia were used
in this study. The clinical strain, J2315, is a representative of the Edinburgh/
Toronto (ET)/12 lineage and belongs to the genomovar III group of B. cepacia
(12, 20). Strain J2540 is an environmental isolate belonging to genomovar II (3).
B. cepacia and Escherichia coli were grown aerobically at 37°C in Luria-Bertani
(LB) broth or on LB agar plates.
Cell invasion assays. The ability of B. cepacia to invade U937-derived macro-
phages and A549 epithelial cells was examined. The U937 line (American Type
Culture Collection) is a human monocytic cell line which differentiates into
macrophage-like cells when treated with phorbol 12-myristate 13-acetate (PMA;
Sigma). The A549 line (American Type Culture Collection) is a human alveolar
epithelial carcinoma cell line. U937-derived macrophages and A549 epithelial
cells were grown in RPMI tissue culture medium containing 10% fetal calf serum
(Gibco-BRL). Invasion assays were performed by a modification of the genta-
micin protection assay originally described by Isberg and Falkow (10). B. cepacia
is resistant to gentamicin, the drug of choice for killing extracellular bacteria in
assays of invasion. However, ceftazidime, in combination with other antibiotics,
has been shown to efficiently kill B. cepacia (2). We found that a combination of
ceftazidime (1 mg/ml) and amikacin (1 mg/ml) incubated with B. cepacia for 2 h
resulted in greater than 99.99% killing (fewer than 20 CFU were recovered with
an initial inoculum of 5.6 3 107 CFU). Bacterial cells, grown to mid-log phase
(optical density at 600 nm of 0.6) and washed with tissue culture medium, were
used to infect confluent monolayers of eucaryotic cells (5 3 105 cells per well) in
24-well tissue culture plates. The infected monolayers were centrifuged (165 3 g
for 5 min) and incubated at 37°C in 5% CO2 for 30 min to allow bacterial entry.
After 30 min of incubation, the monolayers were washed with phosphate-buff-
ered saline (PBS; pH 7.0), and tissue culture medium containing a combination
of amikacin and ceftazidime was added. The monolayers were then incubated for
2 h to kill the extracellular bacteria. After 2 h of incubation, the cell monolayers
were washed with PBS, released by treatment with 10 mM EDTA, and lysed with
0.25% Triton X-100. The intracellular bacteria were quantitated by plating serial
dilutions of the lysate. All quantitative invasion assays were performed in trip-
licate. A noninvasive strain of E. coli, HB101, was routinely used as a negative
control.
Assay of intracellular growth. Bacterial cell suspensions of the strains J2315
and J2540 were inoculated in parallel onto macrophage and epithelial cell mono-
layers at a multiplicity of infection (MOI) of 10:1. After a 30-min incubation, the
infected monolayers were washed with PBS, and tissue culture medium contain-
ing a combination of amikacin (1 mg/ml) and ceftazidime (1 mg/ml) was added;
the monolayers were then incubated for 2 h to kill the extracellular bacteria.
Following 2 h of incubation, the medium was replaced with antibiotic-free tissue
culture medium, and the intracellular bacteria were quantitated over time. At
each time point, the infected monolayers were lysed as described above and the
bacterial titers were determined by serial dilution and plating.
Transmission electron microscopy. Monolayers of U937-derived macrophages
were grown on glass coverslips and infected with B. cepacia. Infected cells were
prepared for microscopy as previously described (19). Briefly, at different time
points postinfection, the infected cell monolayers were gently rinsed with PBS
and fixed with 2% glutaraldehyde. Specimens were postfixed in 1% OSO4,
dehydrated stepwise in ethanol, and embedded in Polybed 812 (Polysciences,
Inc.). Ultrathin sections were prepared by using a diamond knife (Diatome).
Transmission electron microscopy (TEM) studies were carried out with a Phillips
Model CM12 electron microscope operating at 80 keV.
RESULTS
Invasion of U937 macrophages and A549 pulmonary epithe-
lial cells by B. cepacia. The ability of B. cepacia to invade
cultured U937 macrophages and A549 pulmonary epithelial
cells was examined. We first assayed the ability of B. cepacia to
invade U937 macrophages. The B. cepacia clinical strain J2315
entered cultured macrophages with an invasion frequency of
5.82% and was more than 1,000-fold more invasive than the
noninvasive E. coli control strain HB101 (Table 1). The B.
cepacia environmental isolate, J2540, entered cultured macro-
phages with an invasion frequency of 5.49% and was also more
than a 1,000-fold more invasive than the noninvasive E. coli
strain. Thus, both the clinical and environmental isolates of B.
cepacia entered U937-derived macrophages with statistically
indistinguishable invasion frequencies. When the invasion as-
says were repeated with a higher MOI, the invasion frequen-
cies were, again, statistically equivalent (Table 1). Interest-
ingly, the invasion frequency for both strains was reduced at
the higher MOI, suggesting that invasion of macrophages is
saturable. It has previously been shown that B. cepacia entry
into epithelial cells can be saturated (2).
The ability of J2315 and J2540 to enter A549 pulmonary
epithelial cells was also examined. The clinical strain, J2315,
entered cultured epithelial cells with an invasion frequency of
0.15% (MOI 10:1) and was 25-fold more invasive than the
noninvasive E. coli strain (Table 1). The environmental isolate,
J2540 entered cultured epithelial cells with an invasion fre-
quency of 0.024% (MOI 10:1) and was fourfold more invasive
than the noninvasive E. coli control strain (Table 1). When
epithelial cells were infected at a higher MOI, there was a
slight decrease in the invasion frequency for J2315 and a small
increase in the invasion frequency for J2540 (Table 1). Our
findings are consistent with those of Burns et al. (2), who
previously described the ability of another clinical isolate of B.
cepacia to enter A549 cells.
Intracellular growth of B. cepacia. The ability of both the
clinical and the environmental isolates of B. cepacia to enter
cultured human cells with similar invasion frequencies
prompted us to examine their intracellular fates. Intracellular
growth assays were performed by using B. cepacia-infected
U937-derived macrophages and A549 respiratory epithelial
cells. Bacterial cell suspensions of the clinical isolate J2315 and
the environmental isolate J2540 were inoculated onto cell
monolayers at an MOI of 10:1. After 30 min of incubation, the
infected monolayers were washed and tissue culture medium
containing antibiotics was added to kill the extracellular bac-
teria. Following a 2-h incubation, the medium was replaced
with antibiotic-free tissue culture medium, and the ability of B.
cepacia to survive and replicate intracellularly was determined
by quantitating intracellular bacteria at 6-h time points for a
24-h period.
Shown in Fig. 1A are the results of intracellular growth
assays with cultured macrophages. At time zero the number of
intracellular bacteria was similar when macrophages were in-
fected with either J2315 or J2540, a finding consistent with the
similar invasion frequencies of the two strains for macrophages
(Table 1). Following entry, the clinical strain survived and
replicated, with a log unit increase over 24 h in the number of
organisms located intracellularly. In contrast, the environmen-
TABLE 1. Entry of B. cepacia J2315 and J2540 into cultured U937 macrophages and A549 respiratory epithelial cellsa
Strain
U937 Macrophages A549 Epithelial cells
% Invasion (MOI 10:1) % Invasion (MOI 70:1) % Invasion (MOI 10:1) % Invasion (MOI 100:1)
J2315 5.82 6 0.225 3.30 6 0.19 0.15 6 0.0063 0.10 6 0.0019
J2540 5.49 6 0.056 3.16 6 0.35 0.024 6 0.0015 0.034 6 0.0017
E. coli HB101 0.0028 6 0.0005 0.011 6 0.00002 0.0058 6 0.000035 0.0082 6 0.0005
a Invasion assays were performed as described in Materials and Methods. Values represent the percentage of the bacterial inoculum that survived 2 h antibiotic
treatment and are the means 6 the standard deviation of six independent determinations with a total of three wells.
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tal strain, J2540, was killed by macrophages, with a .100-fold
decrease in the number of intracellular bacteria over 24 h. A
similar result was obtained when intracellular growth was as-
sessed on infected A549 epithelial cells (Fig. 1B). Following
entry, the clinical strain survived and replicated, while the
environmental isolate was readily killed.
The integrity of the B. cepacia-infected monolayers was ex-
amined by light microscopy throughout the 24-h period (data
not shown). By 24 h postinfection, visible disruption of the
J2315-infected macrophage and epithelial cell monolayers was
observed, suggesting that J2315 may be cytotoxic to cultured
human cells. Due to the possible loss of host cell viability, time
points beyond 24 h were not measured.
Electron microscopy. TEM confirmed the presence of intra-
cellular B. cepacia. The interaction between the clinical strain
J2315 and U937 macrophages is shown in Fig. 2. At the site of
initial contact between the bacterium and macrophage, a thick-
ening of the cell membrane was visible (Fig. 2A and B). Mi-
crovilli were observed in close association with the invading
bacteria. Invaginations, resembling coated pits (6), were also
visible at the site of contact between the bacterium and the
macrophage (Fig. 2B and C). Intracellular B. cepacia were
observed both singly and in groups and were enclosed in mem-
brane-bound vacuoles (Fig. 2C and D). Many of the bacterial
cells observed by TEM had electron transparent regions that
are likely poly-b-hydroxyalkanoate granules, which are known
to accumulate in B. cepacia (26). By 12 h postinfection there
was significant rounding up of the mitochondria, as well as
vacuolization of the cytosol of infected macrophages (Fig. 2D).
These cytotoxic effects are consistent with the disruption of
J2315-infected monolayers that we observed by light micros-
copy.
Few intracellular bacteria were observed in macrophages
infected with the environmental isolate J2540 (data not
shown). The J2540 cells that were observed intracellularly ap-
peared to be electron dense, suggesting that they were nonvi-
able, a finding consistent with the inability of strain J2540 to
survive intracellularly, as determined by intracellular growth
assays.
DISCUSSION
In this study we established a macrophage model of invasion
and intracellular survival for B. cepacia. We have shown that a
virulent and highly transmissible clinical isolate of B. cepacia,
strain J2315, is able to enter, survive, and replicate intracellu-
larly in cultured human macrophages and pulmonary epithelial
cells. We have also shown that an environmental isolate of B.
cepacia, strain J2540, is able to enter cultured macrophages
and epithelial cells with invasion frequencies similar to those of
the clinical strain. However, in contrast to the clinical strain,
the environmental isolate of B. cepacia is unable to survive or
replicate intracellularly. Our findings provide further evidence
that B. cepacia is a facultative intracellular pathogen with the
capacity to invade and persist in pulmonary epithelial cells and
macrophages. Our data clearly suggest that intracellular sur-
vival and replication contribute to the virulence potential of
pathogenic strains of B. cepacia.
To our knowledge, this is the first report describing the
ability of B. cepacia to enter and survive intracellularly in
cultured human macrophages. Intracellular survival is a key
component in the pathogenic cycle of a number of bacterial
pathogens, including Mycobacteria spp., Shigella flexneri, Sal-
monella spp., and Legionella pneumophila. The mechanisms by
which intracellular pathogens resist killing by macrophages
include inhibition of phagosome-lysosome fusion, escape into
the cytoplasmic compartment, and resistance to reactive oxy-
gen intermediates and lysosomal enzymes (4, 13). The intra-
cytoplasmic B. cepacia cells we observed in infected macro-
phages were all enclosed in membrane-bound vacuoles.
Interestingly, in respiratory epithelial cells, B. cepacia cells are
also found enclosed in membrane-bound vacuoles (2). This
may indicate that B. cepacia intracellular survival does not
require escape into the cytoplasmic compartment but rather
that B. cepacia is able to survive or inhibit the antimicrobial
response of macrophages. It has recently been shown that the
melanin-like pigment produced by epidemic strains of B. ce-
pacia is able to scavenge superoxide anion, which may allow B.
cepacia to survive the respiratory burst response of phagocytic
cells (27). Resistance to nonoxidative killing has been sug-
gested by the ability of B. cepacia to cause invasive infections in
patients with chronic granulomatous disease, an inherited dis-
order of phagocytes in which polymorphonuclear leukocytes
are unable to generate microbicidal oxygen radicals (24).
Intracellular survival does not appear to be a function com-
mon to all strains of B. cepacia. We have shown that the
FIG. 1. Intracellular growth of B. cepacia in U937 macrophages (A) and
A549 respiratory epithelial cells (B). Intracellular growth assays were performed
as described in Materials and Methods. Brackets represent standard errors. Time
zero is 2 h and 30 min postinfection.
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environmental isolate J2540 is able to enter cultured epithelial
cells and macrophages but is unable to survive intracellularly.
Thus, both the clinical and the environmental isolates of B.
cepacia are able to gain entry into cultured human cells, but
they differ in their abilities to survive intracellularly. B. cepacia
CF isolates have been demonstrated to be clonally distinct
from environmental isolates based on both phenotypic and
genetic typing methods (12, 15). However, the pathogenic po-
FIG. 2. Transmission electron micrographs of U937 macrophages infected with B. cepacia J2315. Monolayers were infected with bacteria at an MOI of 10:1. The
infected monolayers were then prepared for electron microscopy at different time points postinfection. (A and B) Initial contact of bacterial cells with the macrophage
surface. (C) Intracellular B. cepacia within a membrane-bound vacuole (20-min postinfection). (D) B. cepacia-infected macrophage containing numerous intracellular
bacteria within a single membrane-bound vacuole (12 h postinfection). The arrows denote invaginations resembling coated pits.
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tential of environmental isolates of B. cepacia has not been
extensively addressed. Our findings suggest that a phenotypic
distinction between strains of B. cepacia may be in their ability
to survive intracellularly in human cells. Differences in the
ability to survive intracellularly may have implications for our
understanding of the varied disease progressions associated
with B. cepacia infections in CF.
We found that the invasion frequency of B. cepacia is sig-
nificantly greater for cultured macrophages than for epithelial
cells, suggesting that distinct or additional mechanisms medi-
ate B. cepacia entry into cultured macrophages. One of the
principal uptake mechanisms of macrophages is phagocytosis,
which involves the uptake of particles coated with complement
and/or antibodies. Binding of complement to the intracellular
pathogens L. pneumophila and Mycobacterium spp. facilitates
their entry into phagocytic cells (1, 23). While we have no
direct evidence that complement-mediated phagocytosis is in-
volved in the internalization of B. cepacia, we did find that
when heat-inactivated serum was used in the invasion assay,
entry of B. cepacia was significantly impaired, suggesting that
macrophage entry may involve complement deposition (un-
published). Another principle uptake mechanism of phagocytic
cells is receptor-mediated endocytosis, which involves special-
ized regions of the eucaryotic surface membrane, known as
coated pits (6). Receptors cluster in these pits which, upon
binding to small particles, invaginate into the cell during en-
docytosis. We observed, by TEM, structures resembling coated
pits at the site of contact between invading bacteria and mac-
rophages (Fig. 2B and C). Their association with invading B.
cepacia suggests they may play a role in the entry process.
Further studies are necessary to confirm the identity of these
structures and to determine their relationship with B. cepacia
entry into macrophages.
TEM of J2315-infected macrophages revealed considerable
vacuolization of the macrophage cytosol at 12-h postinfection
(Fig. 2D). Similar morphological changes have been observed
in macrophages infected with the intracellular pathogens Sal-
monella typhimurium and S. flexneri (16, 28). These morpho-
logical changes result from bacterium-mediated induction of
apoptosis (programmed cell death). Induction of programmed
cell death by bacterial pathogens is believed to play a role in
both immune system evasion and the initiation of inflamma-
tion (29). In the case of S. typhimurium, apoptosis is triggered
upon macrophage entry, while S. flexneri induces apoptosis
upon escape from the phagosome into the macrophage cyto-
plasm (16, 28). Extensive vacuolization of the macrophage
cytosol was not observed at early stages of B. cepacia infection
(Fig. 2A to C), indicating that the observed morphological
changes may occur at stages during or subsequent to entry. It
is noteworthy that J2315 produces a hemolytic toxin that has
been shown to induce apoptosis in cultured macrophages (9).
It has been proposed that the induction of apoptosis may
enhance the establishment of B. cepacia infection by blocking
release of the bacteriocidal contents of phagocytes. The pos-
sible role of apoptosis in the pathogenesis of B. cepacia is
currently under investigation.
The ability of B. cepacia to invade and survive intracellularly
in cultured macrophages and pulmonary epithelial cells clearly
suggests that B. cepacia may have an intracellular phase during
pulmonary infections in CF. Intracellular survival in macro-
phages may play a role in immune evasion. Alternatively, mac-
rophages may serve as a vehicle for translocation and systemic
dissemination of B. cepacia outside of the CF lung. With an
established cell culture model for invasion and intracellular
survival, studies are now possible to further characterize the
mechanisms of pathogenesis and the genetic elements required
for these processes.
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